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Multitarget Stool RNATest for Noninvasive Detection of
Colorectal Neoplasia in a Multicenter, Prospective, and
Retrospective Cohort
Erica K. Barnell, PhD1,2, Yiming Kang, PhD1, Andrew R. Barnell, MBA1, Kimberly R. Kruse, MS1, Jared Fiske, BS1, Zachary R. Pittz, BS1,
Adnan R. Khan, MD3,4, Thomas A. Huebner, MD4,5, Faith L. Holmes, MD4, Malachi Griffith, PhD6,7,8,9, Obi L. Griffith, PhD6,7,8,9,
Aadel A. Chaudhuri, MD, PhD7,9,10 and Elizabeth M. Wurtzler, PhD1
INTRODUCTION: Effective colorectal cancer (CRC) prevention and screening requires sensitive detection of all advanced
neoplasias (CRC and advanced adenomas [AA]). However, existing noninvasive screening approaches
cannot accurately detect adenomas with high sensitivity.
METHODS: Here, we describe a multifactor assay (RNA-FIT test) that combines 8 stool-derived eukaryotic RNA
biomarkers, patient demographic information (smoking status), and a fecal immunochemical test (FIT)
to sensitively detect advanced colorectal neoplasias and other non-advanced adenomas in a 1,305-
patient, average-risk, prospective cohort. This cohort was supplementedwith a22-patient retrospective
cohort consisting of stool samples obtained frompatients diagnosedwith AA or CRC before treatment or
resection. Participants within these cohorts were evaluated with the RNA-FIT assay and an optical
colonoscopy. RNA-FIT test results were compared with colonoscopy findings.
RESULTS: Model performance was assessed through 5-fold internal cross-validation of the training set (n5 939)
and by using the model on a hold out testing set (n5 388). When used on the hold out testing set, the
RNA-FIT test attained a 95% sensitivity for CRC (n 5 22), 62% sensitivity for AA (n 5 52), 25%
sensitivity for other non-AA (n 5 139), 80% specificity for hyperplastic polyps (n 5 74), and 85%
specificity for no findings on a colonoscopy (n 5 101).
DISCUSSION: The RNA-FIT assay demonstrated clinically relevant detection of all grades of colorectal neoplasia,
including carcinomas, AAs, and ONAs. This assay could represent a noninvasive option to screen for
both CRC and precancerous adenomas.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A618.
Clinical and Translational Gastroenterology 2021;12:e00360. https://doi.org/10.14309/ctg.0000000000000360
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer
related deaths in the United States. If detected early, CRC has a 5-
year survival rate of 92%. However, 63% of newly diagnosed
patients have advanced disease, with an associated 5-year survival
rate as low as 14% (1–3). Disease onset is typically insidious,
starting as a small polyp which can take several years to further
accrue somaticmutations anddevelop into an invasive carcinoma
(4–6). For this reason, the detection and resection of adenomas
through colonoscopy significantly reduces morbidity and mor-
tality associated with CRC (7,8). One study estimates that for
every 1% increase in the rate of adenoma detection through
screening, there is a 3% decrease in the rate of cancer de-
velopment (9).
The annual malignant transformation rate of any adenoma is
approximately 0.25% (10). However, advanced adenomas (AA),
which are the most severe category of adenomas, can have an
annual malignant transformation rate between 5% and 50%
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depending on pathological characteristics (10,11). AA are defined
by size (.10 mm) and/or histology on surgical pathology
(villous/tubulovillous growth pattern, high-grade dysplasia, and/
or carcinoma in situ). Although the importance of AA detection
has been extensively recognized, the USMulti-Society Task Force
on CRC recently determined that non-AA/polyps (e.g., 3–4 ad-
enomas,10mmand hyperplastic polyps.10mm) are clinically
relevant and alter the recommended screening interval if dis-
covered via colonoscopy (12). Therefore, detection of all adeno-
mas is an important aspect of CRC screening programs.
Although invasive screening methods (e.g., colonoscopy or
sigmoidoscopy) can detect up to 95% of advanced colorectal
neoplasias (CRC and AA) (13), CRC screening compliance by
colonoscopy has remained stagnant at approximately 60% for
decades (1,14) and nearly a quarter of adults in average-risk
populations have never been screened (3). To combat low com-
pliance, noninvasive screening alternatives have been developed
that evaluate stool- and blood-derived biomarkers.
The fecal immunochemical test (FIT)-DNA test (Cologuard;
Exact Sciences Corporation, Madison, WI) is considered to be the
most accurate of all noninvasive diagnostic tests with 92% sensi-
tivity for CRC and 42% sensitivity for AA, at an 87% specificity
(15). However, recent studies indicate that the accuracy profile of
the FIT-DNA test might not significantly differ frommodern FITs
performed alone (16). In addition, the FIT-DNA test classifies non-
AA as negative findings, despite these lesions having known ma-
lignant potential that impact the patient’s risk-stratified screening
interval recommendation if detected through colonoscopy (12).
Other Food and Drug Administration–approved or –cleared di-
agnostics (fecal occult blood test, FIT, and the plasma Septin9 test
[Epi proColon; Epigenomics, San Diego, CA]) demonstrate com-
parable or inferiormetrics regarding advanced neoplasia detection
(16,17).
Blood-based diagnostics, which evaluate circulating tumor
cells (18), cell-free DNA (19,20), and/or immune markers, are
also being developed to address CRC screening noncompliance,
but existing evidence for these tests highlights a number of
challenges. For example, clinical utility assessments of these tests
are limited to retrospective or case-control cohorts (18,19,21).
Scalability of these diagnostics is unknown because huge feature
pools (whole genome or.100,000 methylome sites) increase the
risk of false discovery and limit reproducibility in prospective
cohorts (19,20). Furthermore, study results typically report on
fewer than 50% of enrolled participants (19,21), implying either
selection bias or inability to scalably evaluate all participants.
Blood-based diagnostics face the additional challenge of de-
termining tumor of origin and demonstrating high sensitivity for
early-stage carcinomas (19). A recent study attempting to address
these concerns showed low sensitivity for early-stage cancer de-
tection (stage I 5 28%), which is compounded by imperfect tu-
mor of origin predictions (19). To date, most blood-based
diagnostics have not assessed sensitivity for adenomas, likely due
to biological and technical barriers, which significantly limits
their utility in the colorectal cancer screening setting (22).
It has been proposed that stool-derived eukaryotic RNA
(seRNA) biomarkers are the ideal platform for detection of co-
lorectal neoplasms because of the transcriptome’s ability to pro-
vides a real-time snapshot of cellular activity using signals that are
exponentially amplified relative to DNA markers (23). In pre-
vious studies, seRNAhas been leveraged to sensitively detect CRC
and non-AA (24,25). Here, we present novel data from a new
cohort that further supports the ability for RNA biomarkers to
accurately identify colorectal lesions in an average-risk asymp-
tomatic population. Using a prospective cohort from a multi-
center clinical trial, the RNA-FIT test demonstrated accurate
detection of colorectal neoplasias when compared with a
screening colonoscopy. A retrospective cohort was used to sup-
plement the accuracy of the RNA-FIT test on patients with ad-
vanced neoplasias. The results suggest that the RNA-FIT test
could improve access to sensitive and specific noninvasive
screening tests for CRC and AA.
METHODS
Study design
This study required prospective collection of stool samples
from participants prior to undergoing average-risk CRC
screening via colonoscopy. Samples were collected up to 60
days before the colonoscopy procedure. In addition, stool
samples were retrospectively obtained from participants who
had been diagnosed with CRC or AA through colonoscopy, but
had not yet been treated for disease. The protocol and research
procedures were approved by the Advarra Institutional Review
Board (IRB #00032825) and the Washington University
School of Medicine Institutional Review Board (IRB
#20111107). The primary objective of the study was to assess
the ability for the RNA-FIT test to detect advanced neoplasias
(CRC and AA), with an emphasis on sensitivity for highly
aggressive precancerous adenomas (AAs with high-grade
dysplasia, carcinoma in situ, or villous/tubulovillous archi-
tecture). The secondary objective was to assess RNA-FIT test
sensitivity for other non-AA (ONA).
Patient eligibility criteria (prospective cohort)
Individuals who were prospectively recruited for this study were
identified by using online engagement platforms. Initial eligibility
was determined through an online survey, and final eligibility was
subsequently confirmed verbally using predetermined criteria
(see Supplementary Methods, Supplementary Digital Content 1,
http://links.lww.com/CTG/A618). For a patient to be considered
for the analysis, it was required that the patient (i) submit a stool
sample, (ii) undergo a screening colonoscopy, and (iii) provide
colonoscopy/histopathology reports, as applicable. If any of these
requirements were not completed, the patient was considered
ineligible. Reports provided by physicians after colonoscopy
procedures (e.g., colonoscopy report, histopathology, and/or
history and physical) were also reviewed to ensure that eligibility
criteria were met.
Patient eligibility criteria (retrospective cohort)
Individuals who were retrospectively recruited for the study were
identified by the Digestive Disease Research Core Center at the
Washington University School of Medicine. Stool samples from
this cohort were subject to the same inclusion criteria as those
identified from the prospective cohort (see Supplementary
Methods, Supplementary Digital Content 1, http://links.lww.
com/CTG/A618).
Demographic characteristics
Demographics, including age, smoking status, sex, family history
of CRC, ethnic background, average income, insurance, and
screening history, were captured using a combination of the
online survey and verbal communication. Some data were
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verified using clinical information from the physician-provided
colonoscopy notes and/or history and physical reports. Geo-
graphic designations were based on linking a patient’s zip code to
the US core-based statistical areas (26,27). Rural areas were de-
fined as containing an urban core of fewer than 10,000 residents.
If a zip code was on the border between rural and urban, the
residential ratio was used to classify the participant as either rural
or urban.
Acquisition of stool samples
Once a patient was enrolled into the study, a stool sample col-
lection kit was sent to the patient’s residence. Participants pro-
duced a stool sample acquired from a single bowel movement,
collected a stool swab for FIT analysis (OC-Light S FIT; Poly-
medco, Cortlandt Manor, NY) in accordance with manufacturer
instructions, and shipped the stool sample in a stabilization buffer
at ambient temperature to a centralized lab (Geneoscopy, St.
Louis, MO). If a sample was produced.96 hours before receipt,
then the sample was considered ineligible.
seRNA biomarker extraction and quantification
Once a stool sample was received, seRNA was extracted based on
previously described methods (24). Briefly, isolation and purifi-
cation of seRNA required differential centrifugation, automated
nucleic acid extraction (EMAG; bioMérieux, Marcy-l’Étoile,
France), and DNAse treatment (Baseline-ZERO DNase, Mid-
dleton, WI). Quantification of seRNA used a digital droplet
polymerase chain reaction system (QXDx AutoDG ddPCR Sys-
tem; Bio-Rad Laboratories, Hercules, CA).
FIT analysis
The OC-Light S FIT (Polymedco; Cortlandt Manor, NY) was
processed in accordance with manufacturer instructions. FIT
assessments were performed by researchers within 30 days of
sample collection by inserting the lateral flow test strip into the
sample bottle and visualizing the experimental line after 5
minutes. If the experimental line was visible and the control
line was visible, then the test was positive. If the experimental
line was not visible and the control line was visible, then the
test was negative. If the control line was not visible, then the
test was considered ineligible. Faint experimental lines and
experimental lines that did not entirely cross the test strip were
considered negative, as described in internal standard oper-
ating procedures.
Risk-stratification of lesions based on optical colonoscopy
and histopathology
Patient classifications were based on risk-stratified disease se-
verity (Table 1) and were generated from colonoscopy and his-
topathology findings (12). Lesion classifications directly reflected
those required by the Food and Drug Administration for other
approved CRC screening diagnostics (15) with updates based on
the most recent US Multi-Society Task Force guidelines (12).
Lesion assessment was performed by 2 blinded independent re-
viewers, and lesion determinations were compared for consis-
tency. As needed, a third independent blinded pathologist was
used to obtain agreement across discordant lesion determina-
tions. Patient classification was performed centrally, with the
same reviewers assessing all colonoscopy/histopathology reports
associated with eligible participants.













CRC (1.0) Stage I–IV CRC 25 (1.7%) 3 (0.3%) 2 (0.6%) 20 (91.0%)
AA (2.1) .10 adenomas (TA 1 SSA1 VA 1 TVA);
adenoma with high-grade dysplasia;
adenoma with carcinoma in situ
7 (0.5%) 3 (0.3%) 3 (0.8%) 1 (4.5%)
AA (2.2) Villous adenoma; tubulovillous adenoma 39 (2.9%) 23 (2.5%) 15 (4.1%) 1 (4.5%)
AA (2.3) Tubular adenoma ≧ 10 mm; 5–10 adenomas
(TA only)
50 (3.8%) 28 (3.0%) 22 (6.0%) 0 (0.0%)
AA (2.4) SSA ≧ 10 mm; 5–10 adenomas (TA1 SSA) 22 (1.7%) 12 (1.3%) 10 (2.7%) 0 (0.0%)
ONA (3.0) 1–2 adenomas (TA 1 SSA) between 5 and
10 mm; .20 hyperplastic polyps
123 (9.3%) 81 (8.6%) 42 (11.5%) 0 (0.0%)
ONA (4.0) 3–4 adenomas (TA 1 SSA) , 10 mm 62 (4.7%) 35 (3.7%) 27 (7.4%) 0 (0.0%)
ONA (5.0) 1–2 adenomas (TA 1 SSA) ≦5 mm 233 (17.6%) 163 (17.4%) 70 (19.1%) 0 (0.0%)
Hyperplastic polyp
(6.1)
≦20 hyperplastic polyps 229 (17.3%) 155 (16.5%) 74 (20.2%) 0 (0.0%)
No findings (6.2) No findings on colonoscopy; No
histopathological abnormalities
537 (40.5%) 436 (46.4%) 101 (27.6%) 0 (0.0%)
Total 1,327 939 366 22
This table enumerates lesion categories for the total study, the prospective training set, the prospective testing set, and the retrospective testing set.
AA, advanced adenoma; CRC, colorectal cancer; ONA, other non-AA; SSA, sessile serrated adenoma/sessile serrated polyp; TA, tubular adenoma; TVA, tubulovillous
adenoma; VA, villous adenoma.
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Data normalization and quality assessment
seRNA quantification data were processed before model input.
All markers were evaluated against internal controls, and ex-
perimental markers were normalized to the housekeeping gene
GAPDH. Samples with a GAPDH# no template control1 0.05
copies/mL were considered as having failed quantification and
were not eligible for model development or assessment.
Machine learning model development and assessment
All eligible features, including seRNAbiomarkers, are provided in
Supplementary Table 1, Supplementary Digital Content 1, http://
links.lww.com/CTG/A618. Primer/probe sequences for all
seRNA biomarkers were previously described (24). Model pa-
rameter and biomarker selections were performed using boot-
strapped grid selection (24). Model performance was initially
assessed using 5-fold internal cross-validation (ICV). This re-
quired splitting the training cohort into 5 even folds with strati-
fied lesion categories, thereby creating 5 ICV-training cohorts
(80% of samples) and 5 ICV-testing cohorts (20% of samples).
The ICV-testing cohorts were designed such that each patient in
the training cohort was only assessed in a single ICV-testing
cohort. The model for each ICV-training set was built using the
parameters and features listed in Supplementary Table 1, Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A618
(24). An optimal threshold for a positive outcome was de-
termined for each ICV model in the training cohort by maxi-
mizing the Youden J statistic for the constrained specificity and
sensitivity (28). ICV performance was assessed by evaluating
point sensitivities for the ICV-testing fold with the median area
under the curve (AUC) (median accuracy) and by evaluating
predictions of all 5 models across all folds (concatenated accu-
racy) (see Supplementary Methods, Supplementary Digital
Content 1, http://links.lww.com/CTG/A618).
Hold out testing set assessment
A final model was trained using all individuals in the training set
and the parameters/features defined in Supplementary Table 1,
Supplementary Digital Content 1, http://links.lww.com/CTG/
A618. The ultimate binarization threshold for predicting positive
findings was calculated by maximizing Youden J statistic (28)
within the training set. The model performance was assessed
using a hold out testing set. Point sensitivities, 95% confidence




Participants were recruited for the prospective cohort using vir-
tual enrollment strategies. A total of 1,530 participants were en-
rolled from the 48 contiguous states over the course of 131 days
(October 8, 2019, to February 15, 2020). Of the total participants,
158 (10.3%) did not complete study requirements. Of the
remaining 1,372 evaluable participants, 67 (4.9%) failed the
quality metrics when evaluated by the RNA-FIT test. The
remaining 1,305 participants were split into a 939-patient train-
ing set and a 366-patient hold out testing set. The study was
performed chronologically, such that the training set comprised
the first 939 participants to complete all requirements, and the
hold out testing set comprised all remaining participants. Par-
ticipants were recruited for the retrospective cohort through the
Digestive Disease Research Core Center at the Washington
University School ofMedicine. In total, 22 samples were obtained
from patients after diagnosis of CRC or AA but before surgical
resection or chemotherapy. All samples from the retrospective
cohort (n5 22) were used in the hold out testing set (Table 1 and
Figure 1).
Participant demographics
Demographics for the 1,305 participants in the prospective co-
hort are provided in Supplementary Table 2, Supplementary
Digital Content 1, http://links.lww.com/CTG/A618. The average
age of participants was 55 years (range5 44–80 years), and 63%
were female (37% male). Thirteen percent of participants were
African American, 2.2% were Asian American, 5.6% were His-
panic, 75.4% were white, and 3.1% were of other ethnic back-
grounds; 6.5% of all participants had a family history of CRC.
Figure 1. Flow chart showing patient recruitment. In total, 1,530 patients were prospectively enrolled into the study. Of the 1,530 enrolled participants, 134
were withdrawn from the study because of lack of eligibility (see Supplementary Methods, Supplementary Digital Content 1, http://links.lww.com/CTG/
A618). An additional 24 participants completed the study but were considered ineligible because of failed study logistics (e.g., collection kit was lost in the
mail, collection kit was used improperly). Of the 1,372 participants assessed with the RNA-FITassay, 67 failed RNA quantification (4.9%). No participants
failed FITassessment. The studywas performed chronologically, such that the training set comprised the first 939participants to complete all requirements,
and the hold out testing set comprised all remaining participants. An additional retrospective cohort of 22 samples were collected from patients with known
disease status (CRC or advanced adenoma) before surgical resection or treatment. AA, advanced adenomas; CRC, colorectal cancer.
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Participant accrual was from all 48 contiguous states, which
corresponded to 1,180 zip codes. Approximately 4.3% of partic-
ipants lived in rural areas (26,27). Finally, 21% of the study
population was low income (,$29,999 per year), and 24% of
eligible participants were on public insurance (Medicaid and
Medicare).
Internal cross-validation of the training set
There were 348 participants (37% of total) in the training set who
were considered to have positive colonoscopy findings; CRC (n5
3), AA (n5 66), or ONA (n5 279). Among the participants with
AA, 3were classified as having high-grade dysplasia or carcinoma
in situ, 23 were classified as having tubulovillous or villous ar-
chitecture, 28 had large ($10-mm) tubular adenomas, and 12 had
large ($10-mm) sessile serrated adenomas/sessile serrated pol-
yps. There were 591 participants (63% of total) in the training set
who were considered to have negative findings; hyperplastic
polyps (n 5 155) or no findings on a colonoscopy (n 5 436)
(Table 1).
The performance of 5-fold internal cross-validation in the
training set is shown in Figure 2A. The median accuracy showed
100% sensitivity for CRC, 58% sensitivity for AA, 20% sensitivity
for ONA, 79% specificity for hyperplastic polyps, and 88%
specificity for no findings on a colonoscopy.When evaluating the
aggregated performance of all 5 ICV folds (concatenated accu-
racy), the RNA-FIT assay detected 3 of 3 participants with CRC
(100% sensitivity; CI95% 29%–100%), 39 of 66 participants with
AA (59% sensitivity; CI95%, 46%–71%), and 60 of 279 participants
with ONA (22% sensitivity; CI95%, 17%–26%) (Figure 2B).
Among participants with AA, 100% of participants with high-
grade dysplasia (n 5 3) and 65% of participants with villous or
tubulovillous adenomas (n5 23) were detected as positive using
the RNA-FIT test. This accuracy profile was achieved with 80%
specificity (CI95%, 73%–86%) for hyperplastic polyps (n 5 155)
Figure 2.Model performance on the training set. (a) 5-fold internal cross-validation was performed for the 939-patient training set. Sensitivity was reported
for 3 lesion categories: CRC, advancedadenomas, andother non-AA. Specificitywas reported for 2 lesion categories: hyperplastic polyps andno findings on
a colonoscopy. For each lesion category, the accuracy metric for the ICV-testing cohort in each fold is reported using a green diamond and the accuracy
metric for the median fold is reported with a green bar. The sensitivity/specificity for all folds was determined based on a threshold identified in the ICV-
training cohort using the Youden J statistic (28). Recommended screening intervals (12) and malignant transformation rates (10,11) for the 5 lesion
categories are also reported. (b) The indexprovides lesioncategories (Table 1),medianaccuracy, andconcatenated accuracy for each lesion category in the
testing set (see Supplementary Methods, Supplementary Digital Content 1, http://links.lww.com/CTG/A618). TA, tubular adenoma; TVA, tubulovillous
adenoma; SSA, sessile serrated adenoma/sessile serrated polyp; VA, villous adenoma.
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Figure 3.Model performance on the 388-patient hold out testing set. (a) The box plot shows model output parsed by lesion category. The box encases the
first/third quartile, the bar represents themedian, whiskers represent 1.5 times the interquartile range, and diamonds represent outliers. (b) TheROC curve
showsmodel performance for CRC, advanced adenomas, and other nonadvanced adenomas. Hyperplastic polyps and no findings on a colonoscopy were
considered negative. (c) The index provides lesion categories (Table 1) and total accuracy for each lesion category. (d) Bar plot shows model accuracy
parsedby lesion category. AA, advancedadenomas; AUC, areaunder the curve;CRC, colorectal cancer;ONA, other nonadvancedadenoma;ROC, receiver
operator characteristic; SSA, sessile serrated adenoma; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma.
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and 86% specificity (CI95%, 82%–89%) for no findings on colo-
noscopy (n5 436) (Figure 2B).
Hold out testing set performance
There were 213 participants (55% of total) in the testing set who
were considered to have positive colonoscopy findings; CRC (n5
22), AA (n 5 52), or non-AA (n 5 139). Among the 52 partici-
pants with AA, 4 were classified as having high-grade dysplasia or
carcinoma in situ, 16 were classified as having tubulovillous or
villous architecture, 22 had large ($10-mm) tubular adenomas,
and 10 had large ($10-mm) sessile serrated adenomas. There
were 175 participants (45%of total) in the hold out testing set who
were considered to have negative findings; hyperplastic polyps (n
5 74) or no findings on a colonoscopy (n 5 101) (Table 1).
A final model was built using the 939-participant training set
and used on the 388-patient hold out testing set. The hold out
testing setmodel predictions were correlatedwith disease severity
(Figure 3A). Receiver operator characteristic AUC for CRC, AA,
and ONA was 0.94, 0.76, and 0.57, respectively, when compared
with negative findings (hyperplastic polyps and no findings on
colonoscopy) (Figure 3B). TheRNA-FIT test detected 21 of the 22
participants with CRC (95%; CI95%, 77%–100%); 32 of the 52
participants with AA (62%; CI95%, 47%–75%); and 35 of the 139
participants with ONA (25%; CI95%, 18%–33%). Of participants
with CRC, the RNA-FIT test detected 100% of patients with local
disease (stage I–II) (n 5 6). Of participants with AA, the RNA-
FIT test detected 100% of participants with high-grade dysplasia
(n 5 4) and 63% of participants with villous or tubulovillous
adenomas (n 5 16) (Figure 3C). This accuracy profile was ach-
ieved with 80% specificity (CI95%, 67%–88%) for hyperplastic
polyps (n 5 74) and 85% specificity (CI95%, 77%–91%) for no
findings on a colonoscopy (n 5 101) (Figure 3c, d).
Anecdotal performance compared with other noninvasive
screening tests
Therewere 25 participants whohad received a negative FIT-DNA
test within the 3 years before enrollment in this study. Colono-
scopy results from this study identified 2 participants as having
AA, 11 as having non-AA, and the remaining 12 participants as
having negative findings (hyperplastic polyps or no findings on a
colonoscopy). The RNA-FIT test detected both participants with
AA (100%) as positive and 2 of the 11 participants with non-AA
(18%) as positive. All 12 participants with negative findings
(hyperplastic polyps and no findings on colonoscopy) were
detected as negative (100%) using the RNA-FIT test (Figure 4).
DISCUSSION
The RNA-FIT test presented here represents the first prospective
development study aimed at accurately detecting CRC, AA, and
other non-AAs with high sensitivity and specificity. The con-
clusions from this study are strengthened by the use of a prag-
matic study design, which included collecting stool before
screening colonoscopy; using a patient cohort that matched the
intended use population; using numerous/geographically diverse
test collection and endoscopy sites; using varied reagent lots and
test systems; limiting features used in model development; and
assessing the model performance by setting thresholds within the
folds of the various training cohorts. Unlike many previous de-
velopment studies that use large feature pools, use a highly con-
trolled design, and leverage retrospective/case-control patient
Figure 4. Evaluation of the RNA-FITassay on patients with a previous negative FIT-DNA test within the past 3 years. Pathology category corresponds to the
pathology category defined in Table 1. Patient findings define the number and type of lesions that were observed on colonoscopy. FIT-DNA and RNA-FIT
results show the output of the assays and time of assay occurrence. Performance of the RNA-FITwas derived from either internal cross-validation of the
training set ormodel performance on the hold out testing set. Specificity showspatientswith a negative FIT-DNA result and a negativeRNA-FITresult. Two of
the 11 participants with other nonadvanced adenomas (not depicted here) were detected as positive using the RNA-FIT. SSA, sessile serrated adenoma/
sessile serrated polyp; TA, tubular adenoma; TVA, tubulovillous adenoma.
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cohorts (29), the accuracy profile presented here will likely be
maintained as the RNA-FIT diagnostic progresses toward clinical
application.
Virtual enrollment permitted significant advantages relative to
traditional enrollment strategies. Study enrollment was completed
on an expedited timeline (131 days) with high patient compliance
(90% completed study requirements). The patient population for
this study included participants across all 48 contiguous states, and
colonoscopy results were derived from .600 different endoscopy
centers. In addition, virtual enrollment assistedwithovercomingbias
associated with traditional clinical trials by including participants
fromrural areas, participantswith low income, andparticipantswith
varied insurance (30,31). Use of this method for enrollment more
closely approximates the clinical setting, which further supports
reproducibility and clinical utility of the accuracy profile.
The RNA-FIT assay has increased ability to detect AAs that
have a highmalignant transformation rate. In the hold out testing
set, the RNA-FIT assay detected 62% of all AAs, which represents
a significant improvement relative to existing alternatives (OC
FIT-CHECK 5 24% sensitivity (15), FIT-DNA test 5 42% sen-
sitivity (15), and plasma septin-9 test5 22% sensitivity (17)). The
importance of this improvement is evidenced by evaluating the
1,680,000 patients who were screened using a noninvasive FIT-
DNA test in 2019 (32). Relative to the FIT-DNA test, which is
currently the most sensitive noninvasive screening alternative,
the RNA-FIT test would have returned positive results on 26,880
additional patients with AA. Given an estimated annual trans-
formation rate of 5%, the RNA-FIT assay could prevent cancer
development in up to 4,032 additional patients over a 3-year
screening interval (11). Even in this modestly sized study of 1,305
prospective participants, the RNA-FIT test identified 2 patients
withmultiple aggressiveAAs and a negative FIT-DNA test within
the past 3 years. The positive result of the RNA-FIT assay for these
2 patients would have resulted in a recommendation for a colo-
noscopy to have these lesions removed (Figure 4).
Ultimately, implementation of the RNA-FIT test might im-
prove the efficacy of CRC screening on several fronts. Noninvasive
stool-based screening options can increase patient compliance
through a patient-friendly, at-home sample collection (33). In
addition, for individuals who require a colonoscopy to remove
lesions, positive noninvasive tests before a colonoscopy have been
shown to increase adenomadetection rates (34).Most importantly,
using the highly sensitive RNA-FIT assay presented here, of the
28% of participants who would have been referred for a colono-
scopy,more than 68%would have had an adenoma or a carcinoma
removed. More importantly, the 72% of participants with a nega-
tive RNA-FIT assay could have been followed noninvasively
without missing the vast majority of participants with CRC, car-
cinoma in situ, or high-grade dysplasia. In a clinical setting where
noninvasive tests are not used for CRC screening, up to 40% of
patients will elect to forgo the recommended colonoscopy, and of
those who do complete the procedure, only 41% would have had a
malignant or premalignant lesion removed.
There were several limitations of this study that can be
addressed through follow on research. First, the use of virtual en-
rollment includes increasednoise fromusinghundreds ofdisparate
sites with differing standard protocols for colonoscopy procedures,
varyingmethods for colonoscopy reporting, and varying adenoma
detection rates (35). An additional limitation of this study includes
the limited number of patients with CRC and the use of retro-
spective cancer samples to ascertain cancer sensitivity. Finally, it
was observed that specificity for no findings on a colonoscopy was
slightly reduced relative to existing screening alternatives (86%
specificity in the training set and 85% specificity in the testing set).
Given the increased sensitivity of the RNA-FIT assay for both AA
and non-AA, it is possible that this reduction in specificity was
partially attributable to missed adenomas on colonoscopy (13).
This is supported by the observation that false-positive RNA-FIT
results had a 28% reduction in colonoscopywithdrawal timeswhen
compared with true-negative RNA-FIT results (8.1 vs 10.4 mi-
nutes; 1-sided t test P value5 0.085) (36).
The RNA-FIT assay presented here provides a robust method
to noninvasively detect colorectal neoplasms with high sensitivity
and specificity. Using ICV of a 939-patient training set and val-
idation on a 388-patient hold out testing set, we demonstrated
significant improvement relative to existing noninvasive diag-
nostics across all cancerous and precancerous lesions: 95% sen-
sitivity for CRC, 62% sensitivity for AA (100% of AA with high-
grade dysplasia and/or carcinoma in situ), and 25% sensitivity for
ONA.Accurate detection of precancerous lesions in a prospective
screening population demonstrates the potential for an RNA-FIT
diagnostic to prevent CRC development through adenoma de-
tection. Analytical and clinical validation of the RNA-FIT di-
agnostic is currently underway to further substantiate that this
noninvasive test could serve as a valuable tool to prevent and
detect cancer as part of routine CRC screening.
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Study Highlights
WHAT IS KNOWN
3 Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the United States; however, CRC
screening compliance by colonoscopy has remained
stagnant at approximately 60% for decades. Noninvasive
screening alternatives have a high sensitivity for CRC (up to
92%); however, there is a significant reduction in sensitivity
for small CRCs, advanced adenomas, and other
precancerous lesions relative to colonoscopies.
WHAT IS NEW HERE
3 Use of a decentralized enrollment strategy permitted
appropriate representation of women,minorities, participants
with low income, and participants in rural areas, which
reduced recruitment bias in this study. Using a prospectively
collected hold out test set, the multifactor assay (RNA-FIT
test) detected 21 of 22 participants with CRC (95%), 32 of 52
participants with advanced adenomas (62%), and 35 of 139
participants with other precancerous adenomas (25%).
3 For all malignant and premalignant lesions, the RNA-FIT test
demonstrated the highest accuracy profile ever reported in a
prospective cohort for a noninvasive CRC screening test.
TRANSLATIONAL IMPACT
3 Detection of precancerous adenomas using the RNA-FIT test
could reduce CRC morbidity and mortality through cancer
prevention. Due to its sensitivity for high-risk adenoma and
carcinoma detection, use of the RNA-FIT test could increase
adenoma detection rate and enhance productivity of
colonoscopies performed.
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